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Abstract. The value of assessing tumor infiltrating lympho-
cytes (TILs) in estrogen receptor (ER) positive/human 
epidermal growth factor receptor type 2 (HER2) negative 
breast cancer has yet to be determined. In the present study, 
a total of 184 cases with early distant recurrence detected 
within 5 years following the primary operation, 134 with 
late distant recurrence diagnosed following 5 years or longer 
and 321 controls without recurrence for >10 years following 
starting the initial treatment for ER‑positive/HER2 negative 
breast cancer, registered in 9 institutions, were analyzed. 
The distributions of TILs and their clinical relevance were 
investigated. TIL distributions did not differ significantly 
among the early, late and no recurrence groups, employing a 
30% cut‑off point as a dichotomous variable. In those who had 
received adjuvant chemotherapy as well as endocrine therapy, 
a trend toward higher TIL proportions was detected when the 
early recurrence group was compared with the no recurrence 
group employing the 30% cut‑off point (P=0.064). The TIL 
distributions were significantly associated with nodal metas-
tasis (P=0.004), ER status (P=0.045), progesterone receptor 
(PgR) status (P=0.002), tumor grade (P=0.021), and the Ki67 
labeling index (LI) (P=0.002) in the no recurrence group and 
with the Ki67 LI in the recurrence groups (P=0.002 in early 
recurrence group, P=0.023 in late recurrence group). High TIL 
distributions also predicted shorter survival time following the 
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detection of recurrence (P=0.026). However, these prognostic 
interactions were not significant in multivariate analysis 
(P=0.200). The present retrospective study demonstrated no 
significant interaction between TIL proportions and the timing 
of recurrence. However, higher TIL proportions were observed 
in breast cancer patients with aggressive biological pheno-
types, which tended to be more responsive to chemotherapy. 
The clinical relevance of stromal TILs for identifying patients 
who would likely benefit from additional therapies merits 
further investigation in a larger patient population.
Introduction
Breast cancer is a heterogeneous disease, which is categorized 
into subtypes according to gene expressions and clinicopatho-
logical features (1,2). Luminal subtype, which is one of the 
recognized subtypes, is characteristically estrogen receptor 
(ER) positive and human epidermal growth factor receptor 
type 2 (HER2) negative. Endocrine therapy is considered 
first, and then chemotherapy in high‑risk groups, based on the 
pathological diagnosis which includes histological classifica-
tion, tumor grade, the Ki67 labeling index (LI) and lymph 
node metastasis, as adjuvant systemic therapies (3,4). However, 
some luminal tumors recur regardless of adjuvant therapy, 
which is a critical problem that must be overcome to improve 
patient survival (5).
The importance of tumor infiltrating lymphocytes (TILs) 
has increasingly been recognized in recent years (6-9). The 
host immune system appears to influence the development 
of breast carcinoma (10). In addition to these observations, 
chemotherapy might trigger recruitment of lymphocytes to 
tumor nests (11,12). We also need to understand whether 
TILs have an important role in patients receiving endo-
crine therapy (13,14). Therefore, we need to understand 
the biological features and functions of TILs in the breast 
cancer microenvironment. Many studies have compared 
TILs among breast cancers to determine their prognostic 
value. Abundant TILs in highly proliferative tumors such 
as triple negative breast cancer and HER2 positive breast 
cancer have been demonstrated (15,16). In a recent study, 
marked TIL infiltration was found to be associated with 
better outcomes for patients with these subtypes (17-23). On 
the other hand, recruitment of TILs was also reported to 
have variable impacts on the outcomes of ER positive/HER2 
negative breast cancers (13,15,24-28). However, details 
of TIL distributions are lacking as there have been few 
studies focusing on the timing of recurrence. In addition, the 
relationships between TIL distributions and the efficacies 
of systemic therapies such as chemotherapy and endocrine 
therapy remain poorly understood.
We retrospectively collected data from ER positive/HER2 
negative breast cancer cases with early and late distant recur-
rence and from patients who remained recurrence free for more 
than ten years, and then identified clinicopathological factors 
predicting early and late recurrence in ER‑positive/HER2 
negative breast cancer cases (29-31). We next investigated the 
biological and prognostic significance of TILs, by comparing 
these three groups. We compared proportions of TILs among 
these groups and investigated associations between TIL distri-
butions and clinicopathological factors in each group.
Materials and methods
Cases and clinical samples. This retrospective multi‑institution 
study was conducted as Scientific Research of the Japanese 
Breast Cancer Society (29,30). We registered 223 consecutive 
patients with early distant recurrence and 149 consecutive 
patients with late distant recurrence of ER‑positive/HER2 
negative breast cancer, who had undergone breast surgery 
and/or neoadjuvant chemotherapy between January 2000 
and December 2004, from nine institutions. These institutes 
were Okayama University, the Cancer Institute Hospital, 
the Japanese Foundation for Cancer Research, Hokkaido 
University, Juntendo University, National Health Organization 
(NHO) Osaka National Hospital, Kumamoto University, 
Kumamoto City Hospital, the NHO Hokkaido Cancer Center, 
and Nagoya City University. Early recurrence was diagnosed 
based on distant metastasis within 5 years, late recurrence as 
distant metastasis more than 5 years after initial treatment. 
For each late recurrence patient, in general, two age‑matched 
patients free of recurrence for more than ten years were 
randomly selected using RAND in combination with Excel 
software at each institution. In total, 321 patients who had been 
recurrence free for more than ten years served as study controls. 
The study protocol was approved by the institutional review 
board (IRB) of each participating institution and conformed to 
the guidelines of the 1996 Declaration of Helsinki. Opting out 
and a waiver of informed consent were options, as anonymized 
archival specimens were used in this retrospective study.
Expressions of ER, PgR, HER2, and Ki67 LI were centrally 
assessed employing immunohistochemistry. HER2‑positive 
tumors were excluded from this study. The details were docu-
mented in our previous report (30).
Hematoxylin and eosin (H&E) stained sections were 
available from 639 of the registered patients (early recurrence: 
n=184, late recurrence: n=134, no recurrence: n=321). In these 
cases with available sections, TIL proportions were compared 
among the three groups. We also assessed the relationships 
between TIL proportions and other clinicopathological 
features. Moreover, the relationship between TIL proportions 
and survival time after recurrence was evaluated for both 
groups with recurrent disease, i.e., both late and early recur-
rence.
Evaluation of TILs. H&E‑stained sections were utilized for 
evaluation of TILs. The percentages of stromal lymphocytes, 
serving as a predefined criterion in Denkert's et al and 
Loi's et al reports (8,25,32), were evaluated by two observers. 
Stromal TILs were measured as the percentage of immune 
cells in stromal tissue within the tumor that showed a mono-
nuclear immunological infiltrate (Fig. 1). Heterogeneous 
distributions were documented in almost all of the sections 
examined. Therefore, hot spots, cold spots, and Tertiary 
Lymphoid Structure were not taken into consideration in any 
of the measurements conducted; instead, one representative 
area was selected and evaluated. The findings were categorized 
according to three possible cut‑off points for TIL proportions 
(10, 30, and 50%).
Statistical analysis. Differences in clinicopathological data 
were compared between cases with and without recurrence 
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employing the Chi‑square test. The Chi square test was 
utilized when investigating associations between the TIL 
distribution and clinicopathological features in each group. 
The Kaplan‑Meier method was used to estimate survival dura-
tion from the time‑point of recurrence detection. Differences 
between overall survival curves were determined with the 
log‑rank test. For both univariate and multivariate analyses, Cox 
regression was used to evaluate the influences of the variables 
on survival time. All of the data were analyzed employing JMP 
11.0.0 (SAS Institute Inc., Cary, NC, USA) statistical software. 
A value of P<0.05 was considered to indicate a statistically 
significant difference.
Results
Patient characteristics. Patient characteristics are presented in 
Table I. The median follow‑up durations were 72 (range, 14‑179), 
133 (range, 67‑177) and 128 (range, 57‑179) months in the early, 
late and no recurrence groups, respectively. During follow‑up of 
these 639 patients, 69.5% (128/184) of those with early recurrence 
and 31.3% (42/134) of those with late recurrence died of breast 
cancer. The histology was invasive ductal carcinoma in 94.0% 
(173/184), 93.2% (125/134) and 93.1% (299/321) of the early, 
late, and no recurrence groups, respectively. The recurrences 
were local in 20.1% (37/184) of the early recurrence group and 
in 28.3% (38/134) of the late recurrence group. Adjuvant endo-
crine therapy alone had been administered to 28.8% (53/184) of 
the early recurrence cases, 41.0% (55/134) of the late recurrence 
cases, and 56.0% (180/321) of the controls, while 53.8% (99/184), 
51.4% (69/134) and 32.3% (104/321), respectively, received both 
adjuvant chemotherapy and endocrine therapy. The adjuvant 
chemotherapy consisted mainly of anthracyclines and/or taxanes.
Distributions of TILs. The TIL distributions are shown in 
Table II. Percentages of TILs did not differ significantly among 
the three groups (P=0.556). In previous reports, various cut‑off 
points were utilized (10, 35, 50 and 60%) (14,25,27,28,33). 
However, there are as yet no standardized cut‑off points. We 
selected a 30% cut‑off point from among the potential values 
because there were few cases with TIL proportions lower than 
10% or more than 50% in our study. We thus conducted the 
following analyses employing 30% as the cut‑off point.
In each case, various adjuvant therapies had been admin-
istered. Therefore, we investigated the TIL distributions 
according to the presence of adjuvant chemotherapy and 
endocrine therapy. The odds ratios for recurrence with high 
TILs are presented in Table III. There were no significant 
interactions between TIL proportions and the time of recur-
rence in any of the subgroups. In those who had received 
adjuvant chemotherapy as well as endocrine therapy, a trend 
toward higher TIL proportions was detected when the early 
recurrence group was compared with the no recurrence group 
employing the 30% cut‑off point (P=0.064).
Associations of TIL proportions with clinicopathological 
factors. We assessed whether the proportion of TILs was 
associated with clinicopathological factors (Table IV). TILs 
in breast cancer specimens correlated significantly with the 
Ki67 LI (P=0.002) in the early recurrence group. Nodal metas-
tasis (P=0.008), tumor grade (P=0.008), and Ki67 LI (P=0.023) 
showed significant associations with the proportion of TILs in 
the late recurrence group. Nodal metastasis (P=0.004), ER 
status (P=0.045), PgR status (P=0.002), tumor grade (P=0.021), 
and Ki67 LI (P=0.002) showed significant associations with the 
proportion of TILs in the no recurrence group.
Survival time after distant recurrence. We analyzed 318 cases 
(early recurrence: 184 (58%), late recurrence: 134 (42%)) to 
compare survival duration from the time of recurrence detec-
tion between the cases with high and low TIL proportions 
(Fig. 2). The median follow‑up duration from the detection 
of recurrence until death due to breast cancer was 39 (0‑141) 
months in the early recurrence and 34 (0‑89) months in the 
late recurrence group. The Kaplan‑Meier method revealed 
a significant difference between these two groups in TIL 
distributions (P=0.026) (Fig. 2). Moreover, the Kaplan‑Meier 
method revealed a trend for higher TIL proportions in the early 
recurrence group (P=0.080), while there was no difference in 
the late recurrence group (P=0.187). Univariate analysis of all 
cases with recurrence revealed TILs, nodal metastasis, and 
tumor grade to be significant prognostic factors. We selected 
significant parameters (P<0.20) from among various conven-
tional confounding factors, and performed a multivariate 
analysis in which nodal metastasis, PgR, tumor grade, and 
Ki67 LI served as categorical variables. In this multivariate 
analysis, lymph node metastasis (P=0.027) was found to be an 
independent prognostic factor, while the proportion of TILs 
was not (P=0.200) (Table V).
Discussion
In this retrospective study, the TIL proportions did not 
vary among recurrence patterns. However, among those 
Figure 1. Hematoxylin and eosin staining of TILs in breast tumor cells. 
Among stromal areas within tumor nests, a small number of TILs ranging 
from 10 to 29% were identified in (A), but in (B) TIL proportions exceeded 
50% (magnification, x400). TILs, tumor infiltrating lymphocytes.
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Table I. Clinicopathological factors according to the time of recurrence.
 Number (%) P‑value
 ------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------
Variable EarR (n=184) LateR (n=134) NoR (n=321) EarR vs. NoR LateR vs. NoR EarR vs. LateR
Age (years)
  ≤50 82 (44.5) 49 (36.5) 120 (37.3) 0.113 0.869 0.151
  >50 102 (55.4) 85 (63.4) 201 (62.6)   
Menopausal status      
  Post‑ 90 (48.9) 81 (60.4) 171 (53.2) 0.345 0.159 0.041a
  Pre‑ 94 (51.0) 53 (39.5) 150 (46.7)   
Bilateral breast cancer      
  Absent 169 (91.8) 121 (90.3) 319 (99.3) <0.001c <0.001c 0.631
  Present 15 (8.1) 13 (9.7) 2 (0.6)   
cT (mm)      
  ≤20 49 (26.6) 44 (32.8) 187 (58.2) <0.001c <0.001c 0.23
  >20 135 (73.3) 90 (67.1) 134 (41.7)   
cN      
  Negative 93 (50.5) 79 (58.9) 267 (83.1) <0.001c <0.001c 0.136
  Positive 91 (49.4) 55 (41.0) 54 (16.8)   
Histological type      
  IDC‑NST 171 (92.9) 124 (92.5) 297 (92.5) 0.864 0.995 0.892
  Others 13 (7.0) 10 (7.4) 24 (7.4)   
Estrogen receptor (%)      
  <10 16 (8.7) 10 (7.4) 27 (8.4) 0.396 0.367 0.915
  10‑50 57 (30.9) 43 (32.0) 82 (25.5)   
  ≥50 111 (60.3) 81 (60.4) 212 (66.0)   
Progesterone receptor (%)      
  ≤20% 85 (46.2) 59 (44.0) 133 (41.4) 0.298 0.609 0.701
  >20% 99 (53.8) 75 (55.9) 188 (58.5)   
Tumor grade      
  1 or 2 131 (71.2) 106 (79.1) 278 (86.6) <0.001c <0.001c 0.107
  3 53 (28.8) 28 (20.9) 43 (13.4)   
Ki 67(%)      
  ≤20 136 (73.9) 114 (85.0) 265 (82.5) <0.001c 0.507 0.014a
  >20 48 (26.0) 20 (14.9) 56 (17.4)   
Local recurrence
  Absent 136 (78.6) 96 (71.6) 0   
  Present 37 (21.3) 38 (28.3) 0   
Surgical treatment      
  Total mastectomy 117 (63.5) 78 (58.2) 106 (33.0) 0.076 <0.001c 0.331
  Partial mastectomy 67 (36.4) 56 (41.7) 215 (66.9)   
Radiation therapy      
  Absent 100 (54.3) 92 (68.6) 149 (46.4) <0.001c <0.001c 0.009b
  Present 84 (45.6) 42 (31.3) 172 (53.5)   
Adjuvant treatment      
  None 13 (7.0) 4 (2.9) 30 (9.3) <0.001c <0.001c 0.021a
  Chemotherapy only 19 (10.3) 6 (4.4) 7 (2.1)   
  Endocrine therapy only 53 (28.8) 55 (41.0) 180 (56.0)   
  Combined therapy 99 (53.8) 69 (51.4) 104 (32.4)   
Neoadjuvant      
chemotherapy
  Absent 168 (91.3) 131 (97.7) 305 (95.3) 0.076 0.198 0.011a
  Present 16 (8.7) 3 (2.2) 15 (4.6)   
ONCOLOGY LETTERS  17:  2177-2186,  2019 2181
receiving chemotherapy and endocrine therapy, cases with 
higher TIL proportions tended to have fewer recurrences, 
though the difference did not reach statistical significance. 
In ER positive breast cancer, the significance of TILs for 
predicting recurrence appears to be minor, but those cases 
showing TIL recruitment might benefit from chemotherapy. 
Higher proportions of TILs were also observed in cancers 
showing markedly proliferative phenotypes. Further study is 
needed to identify associations among lymphocyte recruit-
ment, aggressive features of the tumor and responsiveness to 
chemotherapy.
Many researchers have focused on the significance of differ-
ences in TIL proportions among breast cancer cases (7,34). 
Methods for TIL evaluation varied among these studies. The 
methods used ranged from evaluation of H&E sections for 
lymphocyte density and area, immune cell typing with immu-
nohistochemistry and immune cell related transcriptome 
techniques (35-43). Many previous studies showed higher 
proportions of TILs to be observed in such de‑differentiated 
tumors as triple negative breast cancer (25,33,44). As to patho-
logical examinations, tumor grade and Ki67 LI both correlated 
with higher TIL proportions (25). However, in those with triple 
negative breast cancer, higher TIL proportions also indicated 
a better prognosis according to several reports (44,45), while 
one study found that in ER positive breast cancer accompanied 
by less recruitment of TILs than the triple negative subtype, 
the TIL proportions lacked prognostic significance (46). On 
the other hand, according to a few studies, TILs also corre-
lated with the outcomes of patients with ER positive breast 
tumors (14,33). The conflicting results obtained in these 
studies may reflect different study populations and evalua-
tion methods. We utilized H&E‑stained sections to evaluate 
representative densities of lymphocytes in the stromal area. 
The data obtained in this case control study of luminal breast 
tumors were analyzed by comparing TIL proportions among 
recurrence patterns. We also evaluated time of recurrence in a 
long‑term follow‑up study.
In our full study population, TILs showed no correlation 
with the timing of recurrence. However, among those receiving 
chemotherapy and endocrine therapy, cases with higher TIL 
proportions tended to experience fewer recurrences, though 
the difference did not reach statistical significance. We spec-
ulated that patients with breast tumors showing higher TIL 
Table I. Continued.
 Number (%) P‑value
 ------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------
Variable EarR (n=184) LateR (n=134) NoR (n=321) EarR vs. NoR LateR vs. NoR EarR vs. LateR
Chemotherapy
  A+T 54 (29.3) 22 (16.4) 42 (13.0)   
  A 39 (21.2) 31 (23.1) 40 (12.4)   
  T 6 (3.2) 7 (5.2) 13 (4.0)   
  CMF 17 (9.2) 12 (8.9) 13 (4.0)   
  Others 2 (1.0) 3 (2.2) 3 (0.9)   
  None 66 (35.8) 59 (44.0) 210 (65.4)   
Endocrine therapy      
  TAM 61 (33.1) 34 (25.3) 68 (21.1)   
  TAM+LHRH 30 (16.3) 18 (13.4) 35 (10.9)   
  TAM→AI 16 (8.7) 36 (26.8) 72 (22.4)   
  TAM+LHRH→AI 1 (0.5) 3 (2.2) 15 (4.6)   
  AI 39 (21.2) 27 (20.1) 87 (27.1)   
  LHRH 5 (2.7) 6 (4.4) 7 (2.1)   
  None 32 (17.3) 10 (7.4) 37 (11.5)   
aP<0.05; bP<0.01; cP<0.001. EarR, early recurrence; LateR, late recurrence; NoR, no recurrence; IDC‑NST, invasive ductal carcinoma of no 
special type; A+T, anthracycline and taxane; A, anthracycline; T, taxane; CMF, cyclophosphamide, methotrexate, and fluorouracil; TAM, 
tamoxifen; TAM+LHRH, tamoxifen and luteinizing hormone‑releasing hormone; TAM→AI, tamoxifen followed by aromatase inhibitor; 
TAM+LHRH→AI, tamoxifen and luteinizing hormone‑releasing hormone followed by aromatase inhibitor; AI, aromatase inhibitor; LHRH, 
luteinizing hormone‑releasing hormone; Ki67 Labeling index, Ki67 LI.




TIL positivity EarR LateR NoR P‑value
0‑10% 11 (5.9) 4 (2.9) 17 (5.3) 0.556
10‑30% 151 (82.0) 113 (84.3) 261 (81.3)
30‑50% 19 (10.3) 15 (11.1) 31 (9.6)
50‑100% 3 (1.6) 2 (1.4) 12 (3.7)
EarR, early recurrence; LateR, late recurrence; NoR, no recurrence; 
TILs, tumor infiltrating lymphocytes.
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proportions might benefit more from chemotherapy. ER posi-
tive breast cancer patients received endocrine therapy, which 
was an important aspect of clinical management. Different 
adjuvant therapy modalities might make interpreting the 
Table IV. Proportions of high and low TIL numbers in EarR, LateR, and NoR cases, in association with clinicopathological 
factors.
 Number of TILs (%)
 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 EarR LateR NoR
 ------------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------
Variable High Low P‑value High Low P‑value High Low P‑value
TILs         
  ≤50 12 (54.5) 70 (43.2) 0.317 3 (17.6) 46 (39.3) 0.068 16 (37.2) 104 (37.4) 0.979
  >50 10 (45.4) 92 (56.7)  14 (82.3) 71 (60.6)  27 (62.7) 174 (62.5) 
Tumor size (mm)         
  ≤20 6 (27.2) 43 (26.5) 0.942 4 (23.5) 40 (34.1) 0.369 24 (55.8) 163 (58.6) 0.727
  >20 16 (72.7) 119 (73.4)  13 (76.4) 77 (65.8)  19 (44.1) 115 (41.3) 
Lymph node metastases         
  Negative 11 (50.0) 82 (50.6) 0.956 5 (29.4) 74 (63.2) 0.008b 29 (67.4) 238 (85.6) 0.004
  Positive 11 (50.0) 80 (49.3)  12 (70.5) 43 (36.7)  14 (32.5) 40 (14.3) 
Estrogen receptor (%)         
  <10 1 (4.5) 15 (9.2) 0.622 1 (5.8) 9 (7.6) 0.917 8 (18.60) 19 (6.8) 0.045a
  10‑50 6 (27.2) 51 (31.4)  5 (29.4) 38 (32.4)  12 (27.91) 70 (25.1) 
  ≥50 15 (68.1) 96 (59.2)  11 (64.7) 70 (59.8)  23 (53.49) 189 (67.9) 
Progesterone receptor (%)         
  ≤20% 9 (40.9) 76 (46.9) 0.594 9 (52.9) 50 (42.7) 0.430 27 (62.7) 106 (38.1) 0.002b
  >20% 13 (59.0) 86 (53.0)  8 (47.0) 67 (57.2)  16 (37.2) 172 (61.8) 
Histological grade         
  1 or 2 13 (59.0) 118 (72.8) 0.194 9 (52.9) 97 (82.9) 0.008b 32 (74.4) 246 (88.4) 0.020a
  3 9 (40.9) 44 (27.1)  8 (47.0) 20 (17.0)  11 (25.5) 32 (11.5) 
Ki 67 (%)         
  ≤20 10 (45.4) 126 (77.7) 0.002b 11 (64.7) 103 (88.0) 0.023a 28 (65.1) 237 (85.2) 0.002b
  >20 12 (54.5) 36 (22.2)  6 (35.2) 14 (11.9)  15 (34.8) 41 (14.7) 
aP<0.05; bP<0.01. EarR, early recurrence; LateR, late recurrence; NoR, no recurrence; Ki67, Ki67 Labeling index; TILs, tumor infiltrating 
lymphocytes.
Table III. Odds ratios between recurrence patterns.
 Number with high
 TILs/total number EarR vs. NoR  LateR vs. NoR EarR vs. LateR
 ----------------------------------------------------------- ------------------------------------ ------------------------------------- ---------------------------------------
Adjuvant therapy EarR LateR NoR OR (CI) P‑value OR (CI) P‑value OR (CI) P‑value
All 22/184 17/134 43/321 0.877 (0.499‑1.505)  0.939 (0.502‑1.686) 0.934 (0.476‑1.859)
    P=0.64 P=0.838 P=0.844
CT+ET 13/99 12/69 24/104 0.503 (0.234‑1.041) 0.701 (0.315‑1.494) 0.718 (0.304‑1.703)
    P=0.064 P=0.363 P=0.447
ET 5/53  4/55 15/180 1.145 (0.358‑3.129) 0.862 (0.237‑2.502) 1.328 (0.332‑5.641)
    P=0.803 P=0.862 P=0.684
EarR, early recurrence; LateR, late recurrence; NoR, no recurrence; OR, odds Ratio; CI, confidence interval; CT, chemotherapy; ET, endocrine 
therapy; CT+ET, chemotherapy + endocrine therapy; TILs, tumor infiltrating lymphocytes.
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roles of TILs difficult. Denkert et al (32) defined lymphocyte 
predominant breast cancer (LPBC) as showing evenly and 
widely distributed tumor lymphocytes in tumor nests (16). 
LPBC was defined as a mean density of TILs of at least 50%. 
However, most luminal breast cancers showed heterogeneous 
and low‑density infiltration of lymphocytes into the stromal 
area. Therefore, identifying LPBC might not allow adequate 
evaluation of luminal breast tumors (16). Reliable methods 
for evaluating these heterogeneous distributions and the low 
density of TILs are as yet lacking. According to Vassiliki's 
report, investigation employing a 35% cut‑off point as a 
binary parameter revealed an interaction between high TIL 
proportions and better outcomes, but this interaction was 
not statistically significant (33). According to Denkert's et al 
report, a high proportion of TILs is associated with a high 
pathological complete response rate (27). Jang and Kwon, 
employing a 10% cut‑off value, reported high TIL propor-
tions to be associated with better outcomes for luminal B 
(ER positive, HER2 negative, and higher Ki67) breast cancer 
patients who received adjuvant anthracycline (28). Higher 
TIL recruitment might make cancer cells more responsive to 
chemotherapy. The various cut‑off points need to be investi-
gated in terms of their significance when applied with various 
chemotherapy regimens. Studies utilizing ecological measure-
ments and immune cell typing with immunohistochemistry 
have shown associations of lymphocytes, specifically their 
functions, with patient outcomes (15,35,47‑49). The value 
of H&E‑stained sections for determining lymphocyte 
density and area might be limited because the function of 
lymphocyte recruitment around tumor nests is not revealed 
by this method. Lymphocytes might promote or nega-
tively regulate the growth of tumor nests. Flow cytometry, 
immunohistochemistry, and transcriptome analysis may be 
useful for determining the cell counts of specific lympho-
cyte populations. Further detailed studies, focusing on the 
function, extent and localization of tumor lymphocytes, are 
needed.
According to previous reports, high TIL proportions were 
found in aggressive breast cancer subtypes (15,25). In our 
present study, in each group, TILs were identified in specimens 
from cases with a high Ki67 LI. Moreover, the TIL distribution 
correlated significantly with nodal metastasis, ER status, PgR 
status, tumor grade, and Ki67 LI in the no recurrence group. 
High TIL proportions correlated with rapid tumor growth, 
Table V. Univariate and multivariate analyses for survival time from recurrence detection until mortality due to breast cancer. 
 Hazard ratio
 ----------------------------------------------------------------------------------------------------------------------------------------------------------
Variable Univariate analysis P‑value Multivariate analysis P‑value
TILs ≤30/>30 1.598 (1.028‑2.386) 0.037a 1.348 (0.847‑2.072) 0.200
Age (years) ≤50/>50 1.160 (0.856‑1.581) 0.338 Not selected 
Bilateral breast cancer: absent/present 0.813 (0.438‑1.376) 0.438 Not selected
cT ≤20/>20 1.062 (0.764‑1.503) 0.721 Not selected
cN negative/positive 1.500 (1.109‑2.032) 0.008b 1.412 (1.039‑1.921) 0.027a
PgR <20/≥20 0.789 (0.582‑1.072) 0.130 0.782 (0.575‑1.065) 0.119
Ki67 <20/≥20 1.270 (0.888‑1.781) 0.184 1.176 (0.806‑1.681) 0.391
Tumor grade 1 or 2/3 1.519 (1.080‑2.105) 0.016a 1.385 (0.976‑1.937) 0.066
aP<0.05; bP<0.01. TILs, tumor infiltrating lymphocytes; PgR, progesterone receptor; Ki67, Ki67 Labeling index.
Figure 2. Survival time from recurrence detection until mortality due to 
breast cancer. There were significant differences in the (A) recurrence group 
as a whole. However, there was no significant difference in the (B) early 
recurrence group or in the (C) late recurrence group. TILs, tumor infiltrating 
lymphocytes.
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leading to death from breast cancer recurrence. Studies have 
demonstrated associations between high TIL proportions and 
poorer outcomes (13,26,27). On the other hand, several reports 
have noted an association between TIL proportions and the 
effects of chemotherapy (15). We speculated that infiltration 
and accumulation of TILs might reflect both the aggressive-
ness and the fragility of cancer cells, suggesting that patients 
would benefit from cytotoxic agents. However, minor clusters 
of TILs in luminal breast tumors appear to have little, if any, 
role in recurrence and thus might not be important when 
considering various adjuvant settings. On the other hand, 
patients with breast tumors showing TIL recruitment might 
have a slightly poorer prognosis after recurrence due to the 
aggressive nature of these tumors. Luminal subtype tumors are 
characteristically ER positive and HER2 negative, reflecting 
heterogeneous breast cancer biology. Hormonal treatment is 
considered first, and then chemotherapy in high‑risk groups, 
based on the pathological diagnosis which includes histo-
logical classification, tumor grade, Ki67 LI and lymph node 
metastasis. Therefore, we need to investigate the significance 
of TILs as a predictive factor for selecting therapies such as 
chemotherapy, endocrine therapy and molecular targeted 
therapy among prospective cohorts in a well‑planned adjuvant 
setting. TILs may serve as a surrogate marker for systemic 
therapies. Additional translational research is also required to 
fully investigate the significance of potential TIL biomarkers.
Our study is limited by its retrospective, case control design. 
Therapy selections and intervals varied among physicians. 
Our results might thus have been affected by selection bias. 
Also, our sample was small. Therefore, our conclusions are 
inevitably somewhat controversial. Verification of our findings 
requires a prospective, well‑planned study with a large cohort. 
In the present study, we utilized a predefined cut‑off point to 
categorize the subgroups according to different TIL propor-
tions. This cut‑off point was selected from among potential 
cut‑off value candidates based on our dataset. Therefore, this 
cut‑off point might not be optimal. An optimal cut‑off point 
needs to be established, in a future study, based on the details 
of TIL proportions as a continuous parameter.
In our present study, recruitment of TILs was more often 
observed in aggressive phenotypes, such as ER positive, HER2 
negative breast cancer, but did not significantly predict recur-
rence. However, higher TIL proportions were observed in 
breast cancer patients with aggressive biological phenotypes 
which tended to be more responsive to chemotherapy. The 
significance of stromal TILs for identifying patients likely to 
benefit from additional therapies merits investigation in a large 
future study.
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